CLAIMS

1. A compound of formula I



I

wherein

X is methylene, oxygen, sulphur or a NR^7 group;

R^1 is a straight or branched C_1-C_8 alkyl or C_3-C_8 alkenylene or C_3-C_8 alkynylene chain, optionally substituted with CF_3, phenyl, phenoxy or naphthyl, the aromatic rings optionally substituted by one or more C_1-C_4 alkyl, halogens, trifluoromethyl, hydroxy or C_1-C_4 alkoxy groups;

R^2, R^3 are independently hydrogen, a C_1-C_3 alkyl chain, halogen, trifluoromethyl, hydroxy or C_1-C_4 alkoxy groups;

R^4, R^5, R^6, R^7 are independently hydrogen or C_1-C_6 alkyl;

and the pharmaceutically acceptable salts thereof.

2. Compounds of formula (I) according to claim 1, wherein X is oxygen, methylene, NH or NCH_3, R^1 is C_1-C_8 alkyl chain, optionally substituted with CF_3, phenyl or phenoxy group, where the aromatic ring in R^1 is optionally substituted by one or two halogen or methoxy or trifluoromethyl groups, R^2 and R^3 are hydrogen, methyl, methoxy, fluorine, chlorine or bromine, R^4, R^5 and R^6 are hydrogen or methyl.

3. A compound selected from the group consisting of:

2-(2-benzyloxy-benzylamino)-cyclopentane carboxylic acid amide;

2-(3-benzyloxy-benzylamino)-cyclopentane carboxylic acid amide;

2-(4-benzyloxy-benzylamino)-cyclopentane carboxylic acid amide;

2-[2-(2-Fluoro-benzyloxy)-benzylamino]-cyclopentane carboxylic acid amide;

2-[3-(2-Fluoro-benzyloxy)-benzylamino]-cyclopentane carboxylic acid amide;

cis-2-[3-(2-Fluoro-benzyloxy)-benzylamino]-cyclopentane carboxylic acid amide;

2-[4-(2-Fluoro-benzyloxy)-benzylamino]-cyclopentane carboxylic acid amide;

2-[4-(2-Fluoro-benzylthio)-benzylamino]-cyclopentane carboxylic acid amide;

2-[4-(2-Fluoro-benzylamino)-benzylamino]-cyclopentane carboxylic acid amide;

2-[2-(2-Fluoro-benzyloxy)-3-fluoro-benzylamino]-cyclopentane carboxylic acid amide;

2-[4-(2-Fluoro-benzyloxy)-3-fluoro-benzylamino]-cyclopentane carboxylic acid amide;

2-[2-(2-Fluoro-benzyloxy)-3-chloro-benzylamino]-cyclopentane carboxylic acid amide;

(2-[4-(2-Fluoro-benzyloxy)-3-chloro-benzylamino]-cyclopentane carboxylic acid amide;

(2-[4-(2-Fluoro-benzyloxy)-3-bromo-benzylamino]-cyclopentane carboxylic acid amide;

(2-[4-(2-Fluoro-benzyloxy)-2-methoxy-benzylamino]-cyclopentane carboxylic acid amide;

(2-[4-(2-Fluoro-benzyloxy)-3-methoxy-benzylamino]-cyclopentane carboxylic acid amide;

2-[4-(2-Fluoro-benzyloxy)-3,5-dimethyl-benzylamino]-cyclopentane carboxylic acid amide;

cis-2-[4-(2-Fluoro-benzyloxy)-3,5-dimethyl-benzylamino]-cyclopentane carboxylic acid amide;

and all the stereoisomers and/or pharmaceutically acceptable salts thereof.

4. A process for the preparation of a compound of formula **I**, as defined in claim 1, or a pharmaceutically acceptable salt thereof, the process comprising:

a) reaction of a compound of formula **II**



II

wherein R^1, R^2, R^3 and X are as defined above

with compounds of formula **III**, in the presence of a reducing agent



III

wherein R^4, R^5 and R^6 are as defined previously thus obtaining a compound of formula **I**; or

b) reaction of compounds of formula **IV**



IV

wherein X, R^1, R^2 and R^3 are as defined above and Y is a halogen atom or a O-EWG group, where the EWG means an electron withdrawing group, like e.g. mesyl, tosyl or trifluoroacetyl groups, able to transform the oxygen which they are linked to, in a good leaving group

with compounds of formula **III** thus obtaining a compound of formula **I**; or

c) reacting of a compound of formula **Ia**



Ia

wherein R^1, R^2, R^3, R^5, R^6 and X are as defined above, with compounds of formula **V** or **VI**

R^4Y R^8CHO

V **VI**

wherein Y and R^4 are as defined above; and R^8 is hydrogen or C_1-C_5 alkyl, thus obtaining a compound of the invention in which R^4 is C_1-C_6 alkyl; and, if desired, converting a compound of the invention into another compound of the invention and/or, if desired, converting a compound of the invention into a pharmaceutically acceptable salt and/or, if desired, converting

a salt into a free compound and/or, if desired, separating a mixture of isomers of compounds of the invention into a single isomer.

5. A pharmaceutical composition containing a compound of formula **I**, as defined in claim 1, or a pharmaceutically acceptable salt thereof in admixture with a suitable carrier and/or diluent and optionally to other therapeutic agents.

6. The use of a compound of formula **I**, as defined in claim 1, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament having sodium and/or calcium channel modulating acticity for preventing, alleviating and curing neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where sodium and/or calcium channels are involved in the pathological process.